Alliance for Better Bone Health

U.S. FDA approves prescription risedronate with calcium tabs for osteoporosis

Published in Drug Law Weekly, September 20th, 2005

The U.S. Food and Drug Administration (FDA) approved Actonel with Calcium (risedronate sodium tablets with calcium carbonate tablets, USP), a product that provides the fracture protection of Actonel tablets packaged with calcium tablets.

Actonel with Calcium is a prescription therapy indicated for the prevention and treatment of postmenopausal osteoporosis. Actonel with Calcium includes 4 weeks of therapy. Each week contains 7 tablets, one 35 mg once-a-week Actonel tablet and 6 tablets that each provide 500 mg calcium.

Calcium is a basic building block of bone and is essential for maintaining bone health. Despite this, two new surveys suggest that...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2005-09-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry